ESO Moyamoya Angiopathy Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the European Stroke Organization.

Document Overview

Document Title: Moyamoya Angiopathy

Authoring Society: European Stroke Organization

Document Publication Date: Feb 2, 2023

Page Last Reviewed/Updated: May 6, 2026

Document Type: Guideline

Country of Publication: European

Full Text Freely Available: Yes

Full Text Guideline: journals.sagepub.com/doi/10.1177/23969873221144089

Source Citation: Bersano A, Khan N, Fuentes B, Acerbi F, Canavero I, Tournier-Lasserve E, Vajcoczy P, Zedde ML, Hussain S, Lémeret S, Kraemer M, Herve D. European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy Endorsed by Vascular European Reference Network (VASCERN). Eur Stroke J. 2023 Mar;8(1):55-84. doi: 10.1177/23969873221144089. Epub 2023 Feb 2. PMID: 37021176; PMCID: PMC10069176.

Document Scope, Criteria, and Use Cases

Document Objectives: The aim of this guideline is to provide recommendations guiding stroke clinicians and researchers to ensure the best diagnostic and therapeutic management strategies when assessing patients with a diagnosis of moyamoya angiopathy (MMA), with the final objective of reducing the risk of stroke recurrence and long-term disability.

Scope: Diagnosis, Management, Treatment

Diseases/Conditions (MeSH)

D000080903 - Dual Anti-Platelet Therapy

D009072 - Moyamoya Disease

D000080903 - Dual Anti-Platelet Therapy

D009072 - Moyamoya Disease

Keywords: Antiplatelet therapy (APT), Moyamoya Angiopathy

Target Patient Population: Adult patients and children with moyamoya angiopathy

Target Provider Population: Clinical professionals and specialists directly involved with and responsible for the care of patients with moyamoya angiopathy

Inclusion Criteria: Male, Female, Adult, Child, Older Adult

Health Care Settings: Ambulatory, Hospital

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant